Research from Seoul National University, Department of Internal Medicine has provided new data on acid reflux disease risk factors
2009 JUL 27 - (NewsRx.com) -- Investigators publish new data in the report 'Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive oesophagitis and non-erosive reflux disease.' According to recent research from Korea, "There has been no report on the response to proton pump inhibitor (PPI) therapy and on-demand or the relapse rate of non-erosive reflux disease (NERD) and erosive oesophagitis in Korea. To compare the risk factors, clinical symptoms and PPI responses between patients with erosive oesophagitis and NERD patients." "A survey was performed prospectively in the erosive oesophagitis (205 patients) and NERD group (200 patients). Clinical symptoms, risk factors and PPI responses were analysed. On-demand therapy and the relapse rate of GERD symptoms were investigated during a one-year follow-up. BMI >or=25 (OR 3.0, 95% CI 1.1-8.3), alcohol use (OR 2.9, 95% CI 1.0-8.3), hiatal hernia (OR 5.0, 95% CI 1.2-20) and triglyceride >or=150 mg/dL (OR 4.0, 95% CI 1.7-10) were more common in the erosive oesophagitis group than in the NERD group by multivariate analysis. The ratio of oesophageal to extra-oesophageal symptoms was higher in the erosive oesophagitis group compared with the NERD group (p <0.001). The PPI response rates at 8 weeks were different (p=0.02); refractory rates were higher in the NERD group (16.7%) compared with the erosive oesophagitis group (6.0%). However, there was no significant difference between the two groups in on-demand therapy or the relapse rate," wrote E.S. Lee and colleagues, Seoul National University, Department of Internal Medicine. The researchers concluded: "These results suggest that the underlying pathogenic mechanisms of erosive oesophagitis and NERD are distinct." Lee and colleagues published their study in Alimentary Pharmacology & Therapeutics (Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive oesophagitis and non-erosive reflux disease. Alimentary Pharmacology & Therapeutics, 2009;30(2):154-64). For additional information, contact E.S. Lee, Seoul National University Bundang Hospital, Dept. of Internal Medicine, Seongnam 463-707, Korea. Publisher contact information for the journal Alimentary Pharmacology & Therapeutics is: Blackwell Publishing Inc., 350 Main St., Malden, MA 02148, USA. Keywords: Korea, Acid Reflux Disease Risk Factors, Drugs, Gastroenterology, Hiatal Hernia, Internal Medicine, Oesophagitis, Pharmaceuticals, Pharmacology, Therapies, Therapy, Treatment. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
